7.1. Bibliografia

-Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015; 28:661-72

-Stefanaki C, Soura E, Stergiopoulou A, Kontochristopoulos G, Katsarou A, Potouridou I, Rigopoulos D, Antoniou C, Stratigos A. Clinical and dermoscopic characteristics of congenital melanocytic naevi. J Eur Acad Dermatol Venereol. 2018; 32:1674-1680.

-Krengel S, Scope A, Dusza SW, Vonthein R, Marghoob AA. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol. 2013; 68:441-51.

–Scard C, Aubert H, Wargny M, Martin L, Barbarot S. Risk of melanoma in congenital melanocytic nevi of all sizes: A systematic review. J Eur Acad Dermatol Venereol J Eur Acad Dermatol Venereol. 2023; 37:32-39.

-Cengiz FP, Emiroglu N, Ozkaya DB, Su O, Onsun N. Dermoscopic Features of Small, Medium, and Large-Sized Congenital Melanocytic Nevi. Ann Dermatol 2017; 29:26–32.

-Rogers T, Marino ML, Raciti P, Jain M, Busam KJ, Marchetti MA, Marghoob AA. Biologically distinct subsets of nevi. G Ital Dermatol Venereol. 2016; 151:365-84.

-Viana ACL, Goulart EMA, Gontijo B, Bittencourt FV. A prospective study of patients with large congenital melanocytic nevi and the risk of melanoma. An Bras Dermatol. 2017; 92:200-205.

-Viana AC, Gontijo B, Bittencourt FV. Giant congenital melanocytic nevus. An Bras Dermatol. 2013; 88:863-78.

-Macneal P, Syed HA, Patel BC. Congenital Melanocytic Nevi. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025

-Errichetti E, Patriarca MM, Stinco G. Dermoscopy of congenital melanocytic nevi: a ten-year follow-up study and comparative analysis with acquired melanocytic nevi arising in prepubertal age. Eur J Dermatol. 2017; 27:505-510

-Moustafa D, Blundell AR, Hawryluk EB. Congenital melanocytic nevi. Curr Opin Pediatr 2020; 32: 491-497

-Fortina AB, Zattra E, Bernardini B, Alaibac M, Peserico A. Dermoscopic changes in melanocytic naevi in children during digital follow-up. Acta Derm Venereol. 2012; 92:427-9.

-Corradin MT, Giulioni E, Fiorentino R, Santeufemia DA, Re GL, Vettorello A. In situ malignant melanoma on nevus spilus in an elderly patient. Acta Dermatovenerol Alp Pannonica Adriat. 2014; 23:17-9.

-Kinsler VA, Krengel S, Riviere JB, Waelchli R, Chapusot C, Al-Olabi L, Faivre L, Haenssle HA, Weibel L, Jeudy G, Vabres P. Next-generation sequencing of nevus spilus-type congenital melanocytic nevus: exquisite genotype-phenotype correlation in mosaic RASopathies. J Invest Dermatol. 2014; 134:2658-2660.

-Saha A, Bandyopadhyay D. Nevus of ota. Indian Pediatr. 2014; 51:510.

-Mataix J, López N, Haro R, González E, Angulo J, Requena L. Late-onset Ito’s nevus: an uncommon acquired dermal melanocytosis. J Cutan Pathol. 2007; 34:640-3.

-Strungs I. Common and uncommon variants of melanocytic naevi. Pathology. 2004; 36:396-403.

-Zalaudek I, Catricalà C, Moscarella E, Argenziano G. What dermoscopy tells us about nevogenesis. J Dermatol 2011; 38: 16-24

-Bett BJ. Is removal of melanocytic nevi the optimal treatment strategy? Am Fam Physician. 2009; 80:554.

-Casanova JM, Sanmartín V, Soria X, Baradad M, Martí RM, Font A. Dermatosis infantiles en la consulta de Dermatología de un hospital general universitario en España. Actas Dermosifiliogr. 2008; 99:111-8.

-Lalor L, Busam K, Shah K. Prepubertal Melanoma Arising within a Medium-Sized Congenital Melanocytic Nevus. Pediatr Dermatol. 2016; 33:e372-e374.

-Moreno S, Soria X, Martínez M, Martí RM, Casanova JM. Epidemiology of Melanocytic Naevi in Children from Lleida, Catalonia, Spain: Protective Role of Sunscreen in the Development of Acquired Moles. Acta Derm Venereol. 2016; 96:479-84.

-Levy R, Lara-Corrales I. Melanocytic Nevi in Children: A Review. Pediatr Ann. 2016; 45:e293-8.

-Zalaudek I, Hofmann-Wellenhof R, Kittler H, Argenziano G, Ferrara G, Petrillo L, Kerl H, Soyer HP. A dual concept of nevogenesis: theoretical considerations based on dermoscopic features of melanocytic nevi. J Dtsch Dermatol Ges 2007; 5: 985–992.

-Wazaefi Y, Gaudy-Marqueste C, Avril MF, Malvehy J, Pellacani G, Thomas L, Triller R, Bruneu Y, Monestier S, Richard MA, Fertil B, Grob JJ. Evidence of a limited intra-individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists. J Invest Dermatol 2013; 133: 2355-2361.

-Pizzichetta MA, Soyer HP, Massone C, Cerroni L. Clinical and dermoscopic features of agminated blue nevus. Arch Dermatol. 2007; 143:1225-6.

-Weyant GW, Chung CG, Helm KF. Halo nevus: review of the literature and clinicopathologic findings. Int J Dermatol. 2015; 54:e433-5.

-Requena C, Requena L, Kutzner H, Sánchez Yus E. Spitz nevus: a clinicopathological study of 349 cases. Am J Dermatopathol. 2009; 31:107-16.

-McCarthy SW, Scolyer RA. Melanocytic lesions of the face: diagnostic pitfalls. Ann Acad Med Singapore. 2004; 33(4 Suppl):3-14.

-Harms KL, Lowe L, Fullen DR, Harms PW. Atypical Spitz Tumors: A Diagnostic Challenge. Arch Pathol Lab Med. 2015; 139:1263-70.

-Kerner M, Jaimes N, Scope A, Marghoob AA. Spitz nevi: a bridge between dermoscopic morphology and histopathology. Dermatol Clin. 2013; 31:327-35.

-Bierhoff E. Dysplastischer melanozytärer Nävus. Pathologe. 2015; 36:46-50.

-Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013; 22:528-32.

-Farber MJ, Heilman ER, Friedman RJ. Dysplastic nevi. Dermatol Clin. 2012; 30:389-404.

-Perkins A, Duffy RL. Atypical moles: diagnosis and management. Am Fam Physician. 2015; 91:762-7.

-Casanova JM, Panadés MJ, Ramos J, Salvatella N. Síndrome del nevus displásico con melanoma familiar (tipo D2). Med Clin (Barc). 1989; 92:382-4.

-Rosendahl CO, Grant-Kels JM, Que SK. Dysplastic nevus: Fact and fiction. J Am Acad Dermatol. 2015; 73:507-12.

-Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC; Pigmented Lesion Subcommittee, Melanoma Prevention Working Group. Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. JAMA Dermatol. 2018; 154:1401-1408.

-Mesbah Ardakani N. Dysplastic/Clark naevus in the era of molecular pathology. Australas J Dermatol. 2019. doi: 10.1111/ajd.13019.

-Haenssle HA, Mograby N, Ngassa A, Buhl T, Emmert S, Schön MP, Rosenberger A, Bertsch HP. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas. JAMA Dermatol. 2016; 152:291-8.

-Pandeya N, Kvaskoff M, Olsen CM, Green AC, Perry S, Baxter C, Davis MB, Mortimore R, Westacott L, Wood D, Triscott J, Williamson R, Whiteman DC. Factors Related to Nevus-Associated Cutaneous Melanoma: A Case-Case Study. J Invest Dermatol. 2018; 138:1816-1824.

-Martin-Gorgojo A, Requena C, Garcia-Casado Z, Traves V, Kumar R, Nagore E. Dysplastic vs. Common Naevus-associated vs. De novo Melanomas: An Observational Retrospective Study of 1,021 Patients. Acta Derm Venereol. 2018; 98:556-562.

-Duffy DL, Lee KJ, Jagirdar K, Pflugfelder A, Stark MS, McMeniman EK, Soyer HP, Sturm RA. High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk. Br J Dermatol. 2019. doi: 10.1111/bjd.17833.

-Rishpon A, Navarrete-Dechent C, Marghoob AA, Dusza SW, Isman G, Kose K, Halpern AC, Marchetti MA. Melanoma risk stratification of individuals with a high-risk naevus phenotype – A pilot study. Australas J Dermatol. 2019. doi: 10.1111/ajd.13039

-Watts CG, Madronio C, Morton RL, Goumas C, Armstrong BK, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE. Melanoma: A Population-Based Study. JAMA Dermatol. 2017; 153:23-29.

-Cust AE, Drummond M, Bishop DT, Azizi L, Schmid H, Jenkins MA, Hopper JL, Armstrong BK, Aitken JF, Kefford RF, Giles GG, Demenais F, Goldstein AM, Barrett JH, Kanetsky PA, Elder DE, Mann GJ, Newton-Bishop JA. Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. J Eur Acad Dermatol Venereol. 2019. doi: 10.1111/jdv.15680.

-Salerni G, Carrera C, Lovatto L, Puig-Butille JA, Badenas C, Plana E, Puig S, Malvehy J. Benefits of total body photography and digital dermatoscopy (“two-step method of digital follow-up”) in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012; 67: e17-27

-Dieng M, Smit AK, Hersch J, Morton RL, Cust AE, Irwig L, Low D, Low C, Bell KJL. Patients’ Views About Skin Self-examination After Treatment for Localized Melanoma. JAMA Dermatol. 2019. doi: 10.1001/jamadermatol.2019.0434.

-Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016; 75:967-974.

-Kitchener S, Pinidiyapathirage J, Hunter K, Cochrane L, Gederts S, Sy T, Watts B, Murray A, Poologasundrum M, Bose S, Do A, Hall J, Reedy A, Hudson L, Masel M. Epidemiology of melanoma in rural southern Queensland. Aust J Rural Health. 2019. doi: 10.1111/ajr.12545.

-Rodvall Y, Wahlgren CF, Wiklund K. Future reduction of cutaneous malignant melanoma due to improved sun protection habits and decreased common melanocytic nevi density among Swedish children?: A follow-up from 2002 to 2012. Eur J Cancer. 2019; 118:149-155.

-Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. Am J Public Health 2020; 110:731-733

-Salama AK, Rosa Nd, Scheri RP, Herndon JE, Tyler DS, Marcello J, Pruitt SK, Abernethy AP. The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. Cancer Invest. 2012; 30:637-41.

-Thiam A, Zhao Z, Quinn C, Barber B. Years of life lost due to metastatic melanoma in 12 countries. J Med Econ. 2016; 19:259-64.

-Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014; 28:1005-11.

-Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, Holleczek B, Tryggvadóttir L, Comber H, Bento MJ, Diba ChS, Micallef R, Primic-Žakelj M, Izarzugaza MI, Perucha J, Marcos-Gragera R, Galceran J, Ardanaz E, Schaffar R, Pring A, de Vries E. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 2014; 28:1170-8.

-Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-García C, Rodríguez-Pazos L, Pastushenko I, Marcos-Gragera R, García-Doval I. Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Actas Dermosifiliogr. 2016; 107:318-28.

-Desmond RA, Soong SJ. Epidemiology of malignant melanoma. Surg Clin North Am. 2003; 83:1-29.

-Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, Chirlaque MD, Coza D, Galceran J, Gavin A, Hackl M, Katalinic A, Larønningen S, Louwman MWJ, Morgan E, Robsahm TE, Sanchez MJ, Tryggvadóttir L, Tumino R, Van Eycken E, Vernon S, Zadnik V, Rosso S. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer. 2018; 92:108-118.

-Rimal R, Robsahm TE, Green AC, Ghiasvand R, Rueegg CS, Bassarova A, Gjersvik P, Weiderpass E, Aalen OO, Møller B, Perrier F, Veierød MB. Trends in Invasive Melanoma Thickness in Norway, 1983-2019. Acta Derm Venereol. 2024; 104: adv26110

-Schuurman MS, Hollestein LM, Bastiaannet E, Posthuma EFM, van Akkooi AJC, Kukutsch NA, Aarts MJB, Wakkee M, Lemmens VEPP, Louwman MWJ. Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. Acta Oncol. 2019; 26:1-9.

-Podlipnik S, Carrera C, Boada A, Richarz N, Marcoval J, Ferreres JR, Bodet D, Martí RM, Segura S, Sabat M, Dalmau J, Quintana M, Azon A, Curcó N, Formigon M, Olivella-Garcés MR, Zaballos P, Sola J, Galvany L, Baliu-Piqué C, Alegre M, Pasquali P, Malvehy J, Puig S, On Behalf Of The Network Of Melanoma Centres Of Catalonia. Incidence of Melanoma in Catalonia, Spain, Is Rapidly Increasing in the Elderly Population. A Multicentric Cohort Study. J Clin Med 2020; 9: 3396

-Thrift AP, Gudenkauf FJ. Melanoma incidence among non-Hispanic whites in all 50 United States from 2001 through 2015. J Natl Cancer Inst. 2019 Jul 25. pii: djz153. doi: 10.1093/jnci/djz153.

-Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424.

-GLOBOCAN, en htpps://gco.iarc.fr/today, visitado el 3 de agosto de 2019.

-Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161: 1681-1696.

-Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014; 106: djt435.

-Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014; 28:1005-1111

-Stratigos IA, Champsas G, Panagiotou P, Gogas H, Evangelou E, Tsao H, Stratigos AJ, Stefanaki I. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters. Acta Derm Venereol. 2018; 98:862-866.

-Conejo-Mir J, Moreno JC, Camacho F. Manual de dermatología. Libros princeps. Biblioteca aula médica. 2010.

-Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol 2020; 47:606-616

-Serman N, Vranic S, Glibo M, Serman L, Bukvic Mokos Z. Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review. Bosn J Basic Med Sci 2022; 22:673-682

-Cust AE , Mishra K , Berwick M . Melanoma – role of the environment and genetics. Photochem Photobiol Sci 2018; 17:1853-1860.

-Shitara D, Nascimento MM, Puig S, Yamada S, Enokihara MM, Michalany N, Bagatin E. Nevus-associated melanomas: clinicopathologic features. Am J Clin Pathol. 2014; 142:485-91.

–Bañuls J, Francés L, Niveiro M, Juan G, Schneller-Pavelescu L, Illán F, Sánchez-Payá J, Nagore E, Moreno I, Lallas A, Zaballos P. Heterogeneity in the linear shiny white structures in melanomas seen with polarized light according to histopathological association: Cross-sectional observational study in 118 cutaneous melanomas. J Dermatol. 2020. doi: 10.1111/1346-8138.15457.

-Ciudad-Blanco C, Avilés-Izquierdo JA, Lázaro-Ochaita P, Suárez-Fernández R. Dermoscopic findings for the early detection of melanoma: an analysis of 200 cases. Actas Dermosifiliogr. 2014; 105:683-93.

-Shi K, Kim D, Mohan LS, Garfield EM, Quan VL, Zhang B, Panah E, Compres EV, Khan AU, Gerami P. Retrospective Cohort Study of the Diagnostic Value of Different Subtypes of Atypical Pigment Network on Dermoscopy. J Am Acad Dermatol. 2020:S0190-9622(20)30949-X.

-Paolino G, Bearzi P, Pampena R, Longo C, Frascione P, Rizzo N, Raucci M, Carbone A, Cantisani C, Ricci F, Didona D, Frattini F, Bulotta A, Gregorc V, Mercuri SR. Clinicopathological and dermoscopic features of amelanotic and hypomelanotic melanoma: a retrospective multicentric study. Int J Dermatol. 2020. doi: 10.1111/ijd.15064.

–Đorđević Brlek Z, Jurakić Tončić R, Radoš J, Marinović B. Dermoscopy of Nodular Melanoma: Review of the Literature and Report of 3 Cases. Acta Dermatovenerol Croat. 2016; 24:203-8.

-Argenziano G, Longo C, Cameron A, Cavicchini S, Gourhant JY, Lallas A, McColl I, Rosendahl C, Thomas L, Tiodorovic-Zivkovic D, Zaballos P, Zalaudek I. Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol. 2011; 165:1251-5.

-Pizzichetta MA, Kittler H, Stanganelli I, Bono R, Cavicchini S, De Giorgi V, Ghigliotti G, Quaglino P, Rubegni P, Argenziano G, Talamini R; Italian Melanoma Intergroup. Pigmented nodular melanoma: the predictive value of dermoscopic features using multivariate analysis. Br J Dermatol. 2015; 173:106-14.

-Sgouros D, Lallas A, Kittler H, Zarras A, Kyrgidis A, Papageorgiou C, Puig S, Scope A, Argenziano G, Zalaudek I, Pizzichetta MA, Marghoob A, Liopyris K, Malvehy J, Oikonomou C, Flórez A, Braun R, Cabo H, Nazzaro G, Lanssens S, Menzies S, Paoli J, Kaminska-Winciorek G, Longo C, Katoulis A, Apalla Z, Ioannides D, Thomas L, Tromme I, Ogata D, Desinioti C, Geller A, Stratigos A. Dermatoscopic features of thin (≤ 2mm Breslow thickness) versus thick (> 2mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non-melanoma tumors: a multicentric collaborative study by the International Dermoscopy Society. J Eur Acad Dermatol Venereol. 2020. doi: 10.1111/jdv.16815).

-Menzies SW, Moloney FJ, Byth K, Avramidis M, Argenziano G, Zalaudek I, Braun RP, Malvehy J, Puig S, Rabinovitz HS, Oliviero M, Cabo H, Bono R, Pizzichetta MA, Claeson M, Gaffney DC, Soyer HP, Stanganelli I, Scolyer RA, Guitera P, Kelly J, McCurdy O, Llambrich A, Marghoob AA, Zaballos P, Kirchesch HM, Piccolo D, Bowling J, Thomas L, Terstappen K, Tanaka M, Pellacani G, Pagnanelli G, Ghigliotti G, Ortega BC, Crafter G, Ortiz AM, Tromme I, Karaarslan IK, Ozdemir F, Tam A, Landi C, Norton P, Kaçar N, Rudnicka L, Slowinska M, Simionescu O, Di Stefani A, Coates E, Kreusch J. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol. 2013; 149:699-709.

-Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, Gonzalez A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM. Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia. Int J Dermatol. 2019; 58: 577-581

-Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol. 2005; 125:685-91.

-Martínez-Leboráns L, Garcías-Ladaria J, Oliver-Martínez V, Alegre de Miquel V. Extrafacial Lentigo Maligna: A Report on 14 Cases and a Review of the Literature. Actas Dermosifiliogr. 2016; 107:e57-63.

-Bollea-Garlatti LA, Galimberti GN, Galimberti RL. Lentigo Maligna: Keys to Dermoscopic Diagnosis. Actas Dermosifiliogr. 2016; 107:489-97.

-Costa-Silva M, Calistru A, Barros AM, Lopes S, Esteves M, Azevedo F. Dermatoscopy of flat pigmented facial lesions-evolution of lentigo maligna diagnostic criteria. Dermatol Pract Concept. 2018; 8:198-203.

-Cengiz FP, Cengiz AB, Emiroglu N, Comert E, Wellenhof RH. Dermoscopic and clinical features of head and neck melanoma. An Bras Dermatol. 2015; 90:488-93.

-Lallas A, Lallas K, Tschandl P, Kittler H, Apalla Z, Longo C, Argenziano G. The dermatoscopic inverse approach significantly improves the accuracy of human readers for lentigo maligna diagnosis. J Am Acad Dermatol. 2020 Jun 24:S0190-9622(20)31184-1.

–Madankumar R, Gumaste PV, Martires K, Schaffer PR, Choudhary S, Falto-Aizpurua L, Arora H, Kallis PJ, Patel S, Damanpour S, Sanchez MI, Yin N, Chan A, Sanchez M, Polsky D, Kanavy H, Grichnik JM, Stein JA. Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patients. J Am Acad Dermatol. 2016; 74:724-30.

-Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018; 19:42.

-Kim JY, Choi M, Jo SJ, Min HS, Cho KH. Acral lentiginous melanoma: indolent subtype with long radial growth phase. Am J Dermatopathol. 2014; 36:142-7.

-Alonso A, Ferreres-Riera JR, Marcoval J. Subungual Melanoma: A Descriptive Study of 34 Patients. Actas Dermosifiliogr. 2018. pii: S0001-7310(18)30339-9. doi: 10.1016/j.ad.2018.06.010.

-Levit EK, Kagen MH, Scher RK, Grossman M, Altman E. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol. 2000; 42(2 Pt 1):269-74.

-Boriani F, O’Leary F, Tohill M, Orlando A. Acral Lentiginous Melanoma – misdiagnosis, referral delay and 5 years specific survival according to site. Eur Rev Med Pharmacol Sci. 2014; 18:1990-6.

-Pereda C, Traves V, Requena C, Serra-Guillén C, Llombart B, Sanmartín O, Guillén C, Nagore E. Clinical presentation of acral lentiginous melanoma: a descriptive study. Actas Dermosifiliogr. 2013; 104:220-6.

-Duarte AF, Correia O, Barros AM, Ventura F, Haneke E. Nail melanoma in situ: clinical, dermoscopic, pathologic clues, and steps for minimally invasive treatment. Dermatol Surg. 2015; 41:59-68.

-Phan A, Dalle S, Touzet S, Ronger-Savlé S, Balme B, Thomas L. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br J Dermatol. 2010; 162:765-71.

-Gao F, Xin LL. Dermoscopic features of acral lentiginous melanoma in situ. Chin Med J (Engl). 2019; 132:2123-2124.

-Mun JH, Jo G, Darmawan CC, Park J, Bae JM, Jin H, Kim WI, Kim HS, Ko HC, Kim BS, Kim MB. Association between Breslow thickness and dermoscopic findings in acral melanoma. J Am Acad Dermatol. 2018; 79:831-835.

-Ko D, Oromendia C, Scher R, Lipner SR. Retrospective single-center study evaluating clinical and dermoscopic features of longitudinal melanonychia, ABCDEF criteria, and risk of malignancy. J Am Acad Dermatol. 2019; 80:1272-1283.

-Kaur I, Chowdhry S, D’Souza P, Jakhar D, Yadav MK, Kaur O. Intra-Operative Dermoscopy in Assessment of Melanonychia and as a Guide for Biopsy. Indian Dermatol Online J. 2020; 11:171-176.

-Strazzulla LC, Li X, Zhu K, Okhovat JP, Lee SJ, Kim CC. Clinicopathologic, misdiagnosis, and survival differences between clinically amelanotic melanomas and pigmented melanomas. J Am Acad Dermatol. 2019; 80:1292-1298.

-Merkel EA, Mohan LS, Shi K, Panah E, Zhang B, Gerami P. Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. Lancet Child Adolesc Health. 2019. pii: S2352-4642(19)30116-6.

-Xu JX, Koek S, Lee S, Hanikeri M, Lee M, Beer T, Saunders C. Juvenile melanomas: Western Australian Melanoma Advisory Service experience. Australas J Dermatol. 2017; 58:299-303.

-Haliasos EC, Kerner M, Jaimes N, Zalaudek I, Malvehy J, Hofmann-Wellenhof R, Braun RP, Marghoob AA. Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. Pediatr Dermatol. 2013; 30:281-93.

-Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472-492

-Dixon AJ, Sladden M, Zouboulis CC, Popescu CM, Nirenberg A, Steinman HK, Longo C, Dixon ZL, Thomas JM. Primary Cutaneous Melanoma-Management in 2024. J Clin Med 2024; 13: 1607

-Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206

-Nakamura Y. The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma. Front Med (Lausanne). 2019; 6: 231

-Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C; German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17: 757-767

-Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376: 2211-2222

-Riquelme-Mc Loughlin C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, Barreiro A, Espinosa N, Moreno-Ramírez D, Giavedoni P, Vilana R, Sánchez M, Vidal-Sicart S, Carrera C, Malvehy J, Puig S. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study. J Am Acad Dermatol 2019; 81: 1330-1338

-Tejera-Vaquerizo A, Fernández-Figueras MT, Santos-Briz A, Ríos-Martín JJ, Monteagudo C, Fernández-Flores A, Requena C, Traves V, Descalzo-Gallego MA, Rodríguez-Peralto JL. Protocol for the Histologic Diagnosis of Cutaneous Melanoma: Consensus Statement of the Spanish Society of Pathology and the Spanish Academy of Dermatology and Venereology (AEDV) for the National Cutaneous Melanoma Registry. Actas Dermosifiliogr (Engl Ed). 2021; 112: 32-43

-Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M; European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024. Eur J Cancer 2025; 215: 115153.

-Botella-Estrada R, Boada-García A, Carrera-Álvarez C, Fernández-Figueras M, González-Cao M, Moreno-Ramírez D, Nagore E, Ríos-Buceta L, Rodríguez-Peralto JL, Samaniego-González E, Tejera-Vaquerizo A, Vílchez-Márquez F, Descalzo-Gallego MA, García-Doval I. Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermosifiliogr (Engl Ed). 2021; 112: 142-152

-NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma: Cutaneous Version 2. 2024, 2024. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

–Cancer Council Australia. Clinical practice guidelines for the diagnosis and management of melanoma. https://app.magicapp.org/#/guideline/Lkk3pL

-Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, de la Cruz Merino L, Espinosa Arranz E, García Castaño A, Berrocal Jaime A. SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol 2024 [May 15 Epub ahead of print]. doi: 10.1007/s12094-024-03497-2

-Orme SE, Moncrieff MD. A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management. Cancers (Basel) 2024; 16: 895

-Vaienti S, Calzari P, Nazzaro G. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature. Dermatol Ther (Heidelb) 2023; 13:2187-2215

-Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol 2018; 25:356-377.

–Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023; 29:1310-1312.

-van Akkooi ACJ, Blank C, Eggermont AMM. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. Eur J Cancer 2023; 182:38-42.

-Lorentzen HF. Targeted therapy for malignant melanoma. Current Opinion in Pharmacology 2019; 46: 116-121.

-Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018; 31:24-38.

-Lim SY, Menzies AM, Rizos H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer. 2017; 123(S11):2118-2129.

-Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. Eur J Cancer2023; 194: 13354

-Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017; 22:823-833.

-Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016; 26:232-9

-Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019; 4:e000491

-Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol. 2011; 165:953-65.

-Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014; 5:197-205.

-Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016; 39:98-106.

-Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol. 2019; 10:453.

-Tawbi HA, Schadendorf D, Lipson Evan J, Ascierto Paolo A, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob J-J, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi S, Long GVl. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386: 24-34.

-Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19:1480–92.

-Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017; 35:3807-3814.

-Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol. 2019; 10:726.

-Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017; 18:1202-1210.

-Hao C, Jinhui T, Huiling L, FeiL, Hongxia N, Bingdong Z, Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine 2017; 96:pe7325

-Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019; 15:1111-1122.

-Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez Rutkowski P, Gogas HJ, M.D., Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob J-J, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, M.B., Simonsen KL, Sobiesk AM, Li B, Hodi S, Long GV. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022; 386: 24-34.

-Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Chakrabarty JH, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768

-Bliley R, Avant A, Medina TM, Lanning RM. Radiation and Melanoma: Where Are We Now? Curr Oncol Rep 2024; 26: 904-914.

-Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022; 40(2):127-137.

-Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, de la Cruz Merino L, Espinosa Arranz E, García Castaño A, Berrocal Jaime A. SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol 2024; 26:2841-2855.

–Kobeissi I, Tarhini AA. Systemic adjuvant therapy for high-risk cutaneous melanoma. Ther Adv Med Oncol 2022; 14:1-14.

-Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, Arecco L, Tanda ET, Spagnolo F. The treatment of advanced melanoma: Current approaches and new challenges. Crit Rev Oncol Hematol 2024; 196:104276.

-Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025; 36:10-30.